+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

In vitro inhibition of tumour necrosis factor-alpha and interleukin-6 production by intravenous immunoglobulins

In vitro inhibition of tumour necrosis factor-alpha and interleukin-6 production by intravenous immunoglobulins

British Journal of Haematology 89(4): 698-703

In vitro data about the action of pooled immunoglobulins (Ig) on cytokine (CK) production are controversial. The recent finding of natural antibodies against staphylococcal toxins neutralizing superantigen-induced activation prompted us to design an assay determining their ability to modulate staphylococcal enterotoxin B (SEB) induced CK production (IL-6 and TNF-alpha). Presence of anti-SEB antibodies was demonstrated by a dot-blot assay in the three preparations tested. Preincubation of SEB with pooled Ig prior to addition into the test tube containing PBMCs (neutralizing condition) resulted in a strong inhibition of both TNF-alpha and IL-6 release (TNF alpha: 59 +/- 5% inhibition, P < 0.0001; IL-6: 71 +/- 7% inhibition, P < 0.0001, n = 15). Anti-CD3 MoAb-induced CK production was not modified. During our study it was found that experimental conditions were critical to observe this inhibitory effect. Reversing the previous procedure by adding PBMCs into the test tube containing pooled Ig mixed with SEB resulted in a marked induction of TNF-alpha and IL-6 production. The same observation was made when pooled Ig solely was added (coating condition). F(ab')2 fragments of pooled Ig displayed similar inhibitory capacity when added in neutralizing condition, indicating that the mechanism involved was not Fc dependent. The fragments lost the activating properties of intact Ig when incubated in coating condition, showing that Fc receptor activation occurs in this setting. The present work demonstrates that inhibition of SEB-induced CKs release by pooled Ig can be achieved by SEB neutralization, provided that the experimental conditions avoid activation through the Fc receptor. It can be assumed that similar mechanisms take place in some clinical conditions during which pooled Ig are infused.

Please choose payment method:

(PDF emailed within 1 workday: $29.90)

Accession: 008838238

Download citation: RISBibTeXText

PMID: 7772505

Related references

Reduced in vitro production of interferon-gamma, interleukin-4 and interleukin-12 and increased production of interleukin-6, interleukin-10 and tumour necrosis factor-alpha in systemic lupus erythematosus. Weak correlations of cytokine production with disease activity. Autoimmunity 31(2): 117-124, 1999

Reduced in vitro Production of Interferon-Gamma, Interleukin-4 and Interleukin-12 and Increased Production of Interleukin-6, Interleukin-10 and Tumour Necrosis Factor-Alpha in Systemic Lupus Erythematosus. Weak Correlations of Cytokine Production with Disease Activity. Autoimmunity 31(2): 117-124, 1999

Effect of physical exercise on in vitro production of interleukin 1, interleukin 6, tumour necrosis factor-alpha, interleukin 2 and interferon-gamma. International Journal of Sports Medicine 12(2): 223-227, 1991

Effects of interleukins, colony-stimulating factor and tumour necrosis factor on human hair follicle growth in vitro: a possible role for interleukin-1 and tumour necrosis factor-alpha in alopecia areata. British Journal of Dermatology 135(6): 942-948, 1996

Inhibition of Tumour Necrosis Factor-Alpha and Interleukin-6 Production in Human Monocytes by Iloprost. Anesthesiology Abstracts of Scientific Papers Annual Meeting: Abstract No. A-365, 2002

Inhibition of intracellular tumour necrosis factor -alpha and interleukin -6 production in human monocytes by iloprost. European Journal of Clinical Investigation 33(11): 1013-1017, 2003

Complement activation and release of tumour necrosis factor alpha, interleukin-2, interleukin-6 and soluble tumour necrosis factor and interleukin-2 receptors during and after cardiopulmonary bypass in children. Scandinavian Journal of Clinical and Laboratory Investigation 55(1): 79-86, 1995

Cytokine regulation of human monocyte interleukin 1 il 1 production in vitro enhancement of il 1 production by interferon ifn gamma tumor necrosis factor alpha il 2 and il 1 and inhibition by ifn alpha. Clinical and Experimental Immunology 80(3): 435-443, 1990

Nicotine inhibits the in vitro production of interleukin 2 and tumour necrosis factor-alpha by human mononuclear cells. Immunopharmacology 35(1): 47-51, 1996

Production of interleukin-6 and tumour necrosis factor-alpha in vitro is reduced in whole blood of severely malnourished children. Clinical Science 86(3): 347-351, 1994

Effects of intravenous anesthetics on LPS-induced production of tumour necrosis factor-alpha from primary cultures of rat glial cells in vitro. Zhong Nan Da Xue Xue Bao. Yi Xue Ban 32(3): 413-416, 2007

Enhanced production of tumour necrosis factor-alpha and interleukin-1-beta from monocytes after concomitant exposure to mycobacterial antigens and HIV in vitro. Immunology and Infectious Diseases 6(1): 7-13, 1996

Modulation by dantrolene of endotoxin-induced interleukin-10, tumour necrosis factor-alpha and nitric oxide production in vivo and in vitro. British Journal of Pharmacology 124(6): 1099-1106, 1998

Interleukin-10-secreting CD4 cells from aged patients with AIDS decrease in-vitro HIV replication and tumour necrosis factor alpha production. Aids 21(13): 1763-1770, 2007

Human immunoglobulin preparation for intravenous use induces elevation of cellular cyclic adenosine 3':5'-monophosphate levels, resulting in suppression of tumour necrosis factor alpha and interleukin-1 production. Immunology 72(4): 497-501, 1991